Skip to main content
logo
Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.6402
-0.0101 (-1.55%)
At close: Dec 31, 2025, 4:00 PM EST
0.6600
+0.0198 (3.09%)
After-hours: Dec 31, 2025, 6:45 PM EST

Xilio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Revenue
31.86.34----
Upgrade
Gross Profit
26.266.34----
Upgrade
Selling, General & Admin
28.8324.782729.9523.8610.65
Upgrade
Research & Development
41.2141.2152.1459.251.1943.91
Upgrade
Operating Expenses
70.0465.9979.1389.1575.0454.56
Upgrade
Operating Income
-43.78-59.65-79.13-89.15-75.04-54.56
Upgrade
Interest Expense
-0.1-0.1-0.7-0.8-0.6-0.6
Upgrade
Other Non Operating Income (Expenses)
-15.312.443.431.73-0.16-0.06
Upgrade
EBT Excluding Unusual Items
-58.49-57.3-76.4-88.22-75.8-55.22
Upgrade
Merger & Restructuring Charges
--0.94----
Upgrade
Pretax Income
-58.49-58.24-76.4-88.22-75.8-55.22
Upgrade
Net Income
-58.49-58.24-76.4-88.22-75.8-55.22
Upgrade
Net Income to Common
-58.49-58.24-76.4-88.22-75.8-55.22
Upgrade
Shares Outstanding (Basic)
5254272761
Upgrade
Shares Outstanding (Diluted)
5254272761
Upgrade
Shares Change (YoY)
17.23%94.62%0.38%388.59%970.34%27.97%
Upgrade
EPS (Basic)
-1.13-1.09-2.78-3.22-13.52-105.42
Upgrade
EPS (Diluted)
-1.13-1.09-2.78-3.22-13.52-105.42
Upgrade
Free Cash Flow
-17.58-18.41-69.11-77.59-81.85-38.28
Upgrade
Free Cash Flow Per Share
-0.34-0.34-2.51-2.83-14.60-73.08
Upgrade
Gross Margin
82.58%100.00%----
Upgrade
Operating Margin
-137.64%-940.18%----
Upgrade
Profit Margin
-183.91%-918.05%----
Upgrade
Free Cash Flow Margin
-55.28%-290.26%----
Upgrade
EBITDA
-42.18-58-77.23-87.3-73.55-53.5
Upgrade
D&A For EBITDA
1.591.641.91.851.51.07
Upgrade
EBIT
-43.78-59.65-79.13-89.15-75.04-54.56
Upgrade
Revenue as Reported
31.86.34----
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q